Background

Von Willebrand disease (VWD) is a hereditary bleeding disorder that affects the blood’s ability to clot properly. It is named after Dr. Erik von Willebrand, a Finnish physician who first described the condition in the early 20th century. VWD is one of the most common bleeding disorders and can vary in severity from mild to severe.

Epidemiology

The epidemiology of von Willebrand disease (VWD) can vary by region and population. It is considered one of the most common inherited bleeding disorders. Here are some key epidemiological factors related to VWD:

• Prevalence: The prevalence of VWD differs among populations and regions. It is estimated to affect approximately 1% of the world’s population, making it more common than hemophilia. However, the prevalence can vary, with some populations having a higher incidence.
• Inheritance: VWD follows an autosomal dominant pattern of inheritance. This means that individuals with a family history of the disease are at an increased risk of inheriting it. However, not all individuals with the VWF gene mutation will develop symptoms or have clinically significant bleeding.
• Types: The prevalence of the different types of VWD can vary. Type 1 VWD is the most common and typically less severe form, while Type 3 VWD is the rarest and most severe form. Type 2 VWD is divided into subtypes (2A, 2B, 2M, and 2N), each with its own prevalence and characteristics.
• Age and Gender: VWD can affect individuals of all ages and genders. However, it is often diagnosed in childhood or adolescence, particularly when individuals experience bleeding symptoms after minor injuries or surgeries. There may be a slight female predominance in terms of diagnosis, possibly due to the bleeding associated with menstruation and childbirth.
• Diagnosis and Awareness: VWD is sometimes underdiagnosed or misdiagnosed, especially in mild cases. Increased awareness among healthcare providers and improved diagnostic techniques have led to more accurate diagnoses in recent years.
• Geographic Variations: There may be geographic variations in the prevalence and types of VWD. Some regions may have higher rates due to genetic factors or founder effects, while others may have lower rates.
• Ethnic and Racial Differences: Certain ethnic and racial groups may have a higher or lower prevalence of VWD due to genetic diversity. Research has shown that some populations, such as Ashkenazi Jews, may have a higher prevalence of specific VWF mutations.

Anatomy

Pathophysiology

Von Willebrand disease (VWD) is a genetic bleeding disorder that primarily affects the blood’s ability to clot properly. It is caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein that plays a crucial role in hemostasis, the process that stops bleeding when a blood vessel is injured. VWF has several important functions:

• Platelet Adhesion: VWF helps platelets adhere to the damaged blood vessel wall, forming a temporary plug to stop bleeding.
• Stabilizing Factor VIII: VWF acts as a carrier protein for factor VIII, protecting it from rapid degradation in the bloodstream. Factor VIII is necessary for the formation of blood clots.

There are three primary types of VWD, each with distinct pathophysiological mechanisms:

• Type 1 VWD: This is the mildest form and is characterized by a partial deficiency of VWF. The reduced levels of functional VWF lead to impaired platelet adhesion and a mild bleeding tendency. The pathophysiology involves a quantitative deficiency of VWF due to reduced production or increased clearance.
• Type 2 VWD: This type is characterized by normal or elevated levels of VWF, but the VWF is dysfunctional. Type 2 VWD can be further subdivided into several subtypes (2A, 2B, 2M, and 2N), each with specific abnormalities in VWF function. In these cases, the pathophysiology involves qualitative defects in VWF function, making it less effective in mediating platelet adhesion or factor VIII protection.
• Type 3 VWD: This is the most severe form and is characterized by a near-complete absence of VWF. Individuals with type 3 VWD have very low levels of VWF, leading to a severe bleeding tendency. The pathophysiology involves a quantitative deficiency, where there is little or no functional VWF present.

In all types of VWD, the common pathophysiological consequence is an impaired ability to form stable blood clots, leading to mucocutaneous bleeding (nosebleeds, gum bleeding), easy bruising, and, in severe cases, prolonged or spontaneous bleeding into joints, muscles, or internal organs.

Etiology

VWF plays a crucial role in blood clotting, and any defects in this protein can lead to bleeding problems characteristic of VWD. There are also rare cases of acquired VWD, but they are not as common as the inherited forms.

Here is a more detailed explanation of the etiology of VWD:

• Inherited Genetic Mutations: The most common cause of VWD is inherited genetic mutations in the VWF gene. These mutations can result in one of the three main types of VWD (Type 1, Type 2, or Type 3), each with varying degrees of severity. These mutations can be passed down from parents to their children in an autosomal dominant manner, meaning that a person with one affected gene copy from either parent can develop the condition.
• Type 1 VWD: This form is characterized by reduced levels of VWF due to mutations in one of the VWF gene alleles, leading to a partial deficiency of functional VWF.
• Type 2 VWD: Type 2 VWD is caused by qualitative defects in VWF. There are several subtypes (2A, 2B, 2M, and 2N), each with specific genetic mutations that affect the function of VWF differently.
• Type 3 VWD: This is the most severe form, resulting from mutations that cause a near-complete absence of VWF, leading to very low or undetectable levels of functional VWF.
• Acquired VWD: Acquired VWD is rare and typically occurs due to other underlying medical conditions or factors that temporarily affect VWF function or availability. This can include:
• Autoimmune diseases: In some cases, the body’s immune system mistakenly targets and destroys VWF.
• Medications: Certain medications, such as valproic acid, can reduce VWF levels or impair its function.
• Blood disorders: Conditions like monoclonal gammopathies can interfere with VWF function.

It’s important to note that while genetic mutations are the primary cause of VWD, the severity and clinical presentation of the disorder can vary widely among individuals. Not all individuals with VWF gene mutations will develop clinically significant bleeding symptoms, and the severity of symptoms can be influenced by other genetic and environmental factors.

Genetics

Prognostic Factors

Prognostic factors in von Willebrand disease (VWD) are variables or characteristics that can help predict the likely course and outcomes of the disease in affected individuals. These factors can be important for tailoring treatment and management plans and assessing the long-term outlook. Several prognostic factors are considered in VWD:

• Von Willebrand Disease Type: The specific type of VWD plays a significant role in determining the prognosis. VWD is classified into various types (Type 1, Type 2A, 2B, 2M, 2N, and Type 3), each with different levels of von Willebrand factor (VWF) deficiency or dysfunction. Type 3, which is characterized by a complete absence of VWF, typically has a more severe prognosis than Type 1, which is associated with a partial deficiency.
• Severity of VWF Deficiency: The severity of the VWF deficiency, as measured by laboratory tests such as VWF antigen levels and VWF activity, is a critical prognostic factor. Individuals with lower VWF levels are more likely to experience frequent and severe bleeding episodes.
• Factor VIII Levels: Since VWF plays a role in stabilizing factor VIII (FVIII), the levels of FVIII in the blood can also impact prognosis. Individuals with low FVIII levels may experience more severe bleeding symptoms.
• Bleeding History: The frequency and severity of bleeding episodes experienced by the individual can help predict future bleeding risks. Those with a history of recurrent or severe bleeding may be more likely to experience similar episodes in the future.
• Presence of Inhibitors: The development of inhibitors (antibodies) against VWF or FVIII can complicate the management of VWD and may lead to more severe bleeding episodes. The presence of inhibitors is associated with a poorer prognosis.
• Genetic Mutations: The specific genetic mutations responsible for VWD can influence the prognosis. Some mutations may result in more severe VWF dysfunction, while others may lead to milder forms of the disease.
• Age at Diagnosis: Age at the time of diagnosis can affect the prognosis. Early diagnosis and appropriate management can lead to better outcomes and a reduced risk of complications.
• Response to Treatment: How an individual responds to treatment, such as desmopressin (DDAVP), VWF replacement therapy, or antifibrinolytic medications, can impact their long-term prognosis. Those who respond well to treatment and can effectively control bleeding episodes tend to have a better prognosis.
• Comorbid Conditions: The presence of other medical conditions or comorbidities, such as cardiovascular disease or autoimmune disorders, can influence the prognosis and complicate the management of VWD.
• Access to Healthcare and Adherence to Treatment: Access to specialized care from hematologists or bleeding disorder centers and adherence to prescribed treatment plans are critical factors in managing VWD and improving outcomes.

Clinical History

The clinical history of von Willebrand disease typically includes the following aspects:

• Family History: VWD is often inherited in an autosomal dominant manner, which means that affected individuals usually have a family history of the condition. A detailed family history can help in diagnosing and understanding the genetic basis of the disease.
• Bleeding Symptoms: Individuals with VWD tend to experience a range of bleeding symptoms. These can vary in severity and may include:
• Nosebleeds (epistaxis): Frequent or prolonged nosebleeds, especially in childhood.
• Easy bruising: Bruising easily, even with minor trauma.
• Heavy or prolonged menstrual periods (menorrhagia): Women with VWD may experience heavy and prolonged menstrual bleeding.
• Excessive bleeding after dental procedures: This can include bleeding after tooth extraction or oral surgery.
• Gastrointestinal bleeding: In severe cases, individuals may experience bleeding in the stomach or intestines, leading to blood in the stool or black, tarry stools.
• Excessive bleeding after surgery or injury: Even minor surgical procedures or injuries can result in prolonged bleeding in individuals with VWD.
• Spontaneous Bleeding: In some cases, spontaneous bleeding may occur without an obvious trigger, especially in individuals with more severe forms of VWD.
• Clinical Classification: VWD is classified into different types based on the level and function of von Willebrand factor:
• Type 1 VWD: This is the mildest form, characterized by a partial deficiency of VWF. Bleeding symptoms are usually mild.
• Type 2 VWD: There are four subtypes of Type 2 VWD, each with specific characteristics. In Type 2, there is a qualitative defect in VWF, meaning that the VWF is present but does not function properly.
• Type 3 VWD: This is the most severe form, characterized by a complete absence of VWF. Bleeding symptoms can be very severe and may require more aggressive treatment.
• Diagnosis: The diagnosis of VWD involves a combination of clinical evaluation, family history, bleeding assessment tools, and laboratory tests. Specific blood tests, such as measuring VWF antigen levels, VWF activity, and factor VIII levels, are used to confirm the diagnosis and classify the type of VWD.

Treatment:

Treatment of VWD typically involves:

• Desmopressin (DDAVP): Some individuals with Type 1 VWD may respond well to desmopressin, a medication that stimulates the release of stored VWF and factor VIII.
• Replacement therapy: For more severe forms of VWD or when desmopressin is not effective, replacement therapy with VWF concentrates containing both VWF and factor VIII is used to control bleeding.
• Antifibrinolytic medications: These drugs, such as tranexamic acid, may be used to help prevent or control bleeding by stabilizing blood clots.
• Management and Follow-Up: People with VWD often require ongoing medical management, and their treatment plans may need adjustment based on the severity of their bleeding symptoms and response to treatment. Regular follow-up with a hematologist or specialist in bleeding disorders is important.
• Genetic Counseling: Given the genetic nature of VWD, genetic counseling is often recommended for affected individuals and their families to understand the inheritance pattern and make informed decisions about family planning.

Physical Examination

The physical examination of an individual suspected to have von Willebrand disease (VWD) is an important part of the diagnostic process. While VWD is primarily a bleeding disorder characterized by symptoms like nosebleeds, bruising, and excessive bleeding after minor injuries or surgeries, there are some physical findings that a healthcare provider may look for during the examination. Keep in mind that the diagnosis of VWD relies on a combination of clinical evaluation, laboratory tests, and medical history.

Here are some aspects of the physical examination in the context of VWD:

• Inspection of Skin and Mucous Membranes: The healthcare provider may examine the skin for signs of easy bruising or petechiae (small, red or purple spots under the skin). They may also check the mucous membranes (e.g., inside the mouth) for signs of bleeding, such as gum bleeding or petechiae.
• Nose Examination: Given that frequent nosebleeds (epistaxis) are a common symptom of VWD, the provider may look for any signs of active nosebleeds or signs of previous nosebleeds, such as crusted blood around the nostrils.
• Oral Examination: The healthcare provider may examine the oral cavity, including the gums and the back of the throat, for any signs of bleeding or petechiae.
• Assessment of Joints: While joint bleeding is less common in VWD compared to other bleeding disorders like hemophilia, the provider may assess for any signs of joint swelling, pain, or limited range of motion, which could suggest joint bleeding.
• Assessment of Lymph Nodes and Spleen: In more severe cases of bleeding disorders, enlargement of lymph nodes and spleen may occur due to the accumulation of blood products. This is less likely in VWD but can be assessed during a physical examination.
• Vital Signs: Blood pressure, heart rate, and other vital signs may be measured to ensure the individual is stable and to monitor for any signs of acute bleeding.
• Evaluation of Abdomen: In cases of gastrointestinal bleeding, which can occur in severe forms of VWD, the healthcare provider may perform an abdominal examination to assess for tenderness or masses.
• Assessment of Extremities: The provider may check for any signs of hematoma (collection of blood under the skin) or swelling in the limbs, which can occur after minor injuries or surgery.
• Assessment of Menstrual History: For individuals with VWD, a detailed menstrual history may be obtained to assess for heavy or prolonged menstrual periods (menorrhagia).

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

The differential diagnosis of von Willebrand disease (VWD) involves distinguishing it from other bleeding disorders and conditions that can cause similar symptoms of bleeding. A thorough clinical evaluation, family history assessment, and laboratory testing are essential for making an accurate diagnosis. Here are some conditions and disorders that should be considered in the differential diagnosis of VWD:

• Hemophilia A and B: Hemophilia A and B are genetic bleeding disorders caused by deficiencies in clotting factors VIII and IX, respectively. These conditions can present with similar bleeding symptoms as VWD, but laboratory tests can differentiate them. Measurement of factor VIII and factor IX levels can confirm the diagnosis of hemophilia.
• Platelet Function Disorders: Some platelet function disorders, such as Bernard-Soulier syndrome and Glanzmann thrombasthenia, can lead to bleeding problems similar to VWD. Specialized tests of platelet function, such as platelet aggregation studies, can help differentiate between these disorders and VWD.
• Acquired Platelet Dysfunction: Certain medications, such as aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), as well as medical conditions like uremia (kidney dysfunction), can impair platelet function and cause bleeding. Identifying and addressing the underlying cause or medication is crucial in these cases.
• Hereditary Hemorrhagic Telangiectasia (HHT): HHT is a genetic disorder that can lead to abnormal blood vessel formation and recurrent nosebleeds, gastrointestinal bleeding, and other bleeding symptoms. Family history, clinical evaluation, and genetic testing can help distinguish HHT from VWD.
• Connective Tissue Disorders: Conditions like Ehlers-Danlos syndrome and Marfan syndrome can be associated with bleeding due to vascular fragility. Physical examination and genetic testing may be necessary to differentiate these disorders from VWD.
• Liver Disease: Liver dysfunction can lead to coagulation abnormalities and bleeding. Laboratory tests measuring liver function, as well as tests for coagulation factors and platelet function, can help diagnose liver-related bleeding disorders.
• Vitamin K Deficiency: Deficiency of vitamin K, a crucial component for blood clotting factor synthesis, can lead to bleeding problems. Vitamin K levels and other coagulation tests can identify this condition.
• Acquired Coagulation Disorders: Conditions such as disseminated intravascular coagulation (DIC), which can occur in response to severe infections or other underlying diseases, can result in both bleeding and clotting problems. Laboratory tests and clinical evaluation can determine the underlying cause.
• Medication-Induced Bleeding: Some medications, such as anticoagulants (e.g., warfarin) and antiplatelet drugs (e.g., clopidogrel), can cause bleeding problems. A thorough medication history can help identify potential culprits.
• Thrombocytopenia: Low platelet counts due to conditions like immune thrombocytopenic purpura (ITP) or bone marrow disorders can lead to bleeding. Blood counts and specific tests for platelet function can help diagnose these conditions.
• Other Inherited Bleeding Disorders: Rare bleeding disorders, such as factor XI deficiency, factor VII deficiency, or factor XIII deficiency, should also be considered and ruled out through specialized laboratory tests.

The accurate diagnosis of VWD involves a combination of clinical assessment, bleeding history, family history, and specialized laboratory testing, including measurements of von Willebrand factor (VWF) levels, VWF function, and genetic testing for VWF mutations. Collaboration with a hematologist or bleeding disorder specialist is often necessary to determine the specific bleeding disorder and develop an appropriate treatment plan.

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

The treatment of von Willebrand disease (VWD) aims to prevent or control bleeding episodes and improve the overall quality of life for individuals with this bleeding disorder. Treatment strategies can vary depending on the type and severity of VWD, as well as the specific bleeding symptoms experienced by the patient. Here are the primary treatment options for VWD:

Desmopressin (DDAVP): Desmopressin is a synthetic hormone that stimulates the release of von Willebrand factor (VWF) from storage sites in the body. It is primarily effective for individuals with Type 1 VWD and some subtypes of Type 2 VWD. DDAVP can be administered intravenously (IV), intranasally (nasal spray), or subcutaneously (under the skin). It is often used to treat or prevent bleeding episodes, particularly before minor surgical procedures or dental work. Response to DDAVP can vary among individuals, and it should be used with caution, as it may not be effective for everyone.

Von Willebrand Factor Replacement Therapy: Individuals with more severe forms of VWD (e.g., Type 2B, Type 3) or those who do not respond well to DDAVP may require replacement therapy with VWF-containing products. These products can be administered intravenously and contain purified VWF and factor VIII (FVIII) to correct the deficiency and improve blood clotting. The choice of specific VWF concentrate and dosing regimen depends on the type and severity of VWD and the individual’s response to treatment.

Antifibrinolytic Medications: Antifibrinolytic drugs, such as tranexamic acid or aminocaproic acid, may be prescribed to help prevent or control bleeding episodes. These medications work by stabilizing blood clots and can be particularly useful in cases of mucosal bleeding (e.g., nosebleeds, heavy menstrual bleeding).

Hormonal Therapies: For women with VWD who experience heavy or prolonged menstrual bleeding (menorrhagia), hormonal therapies may be recommended. This can include the use of birth control pills, hormonal intrauterine devices (IUDs), or other hormonal treatments to regulate menstrual cycles and reduce bleeding.

Management of Specific Situations:

• In cases of surgery or major procedures, individuals with VWD should work closely with their healthcare team to develop a comprehensive plan that may include preoperative treatment with DDAVP or VWF replacement therapy.
• Dental procedures often require prophylactic treatment with DDAVP or VWF concentrate.
• For severe bleeding episodes or emergencies, prompt treatment with VWF concentrate and other supportive measures may be necessary.

Regular Follow-Up and Monitoring:

• Individuals with VWD should receive regular follow-up care with a hematologist or specialist in bleeding disorders.
• Monitoring of VWF levels and factor VIII levels may be necessary to assess the effectiveness of treatment and make adjustments as needed.

Lifestyle and Precautions: Patients with VWD should be educated about bleeding prevention strategies, including the use of soft-bristle toothbrushes, avoidance of certain medications (e.g., aspirin), and the importance of informing healthcare providers about their bleeding disorder prior to medical procedures.

Genetic Counseling: Genetic counseling may be recommended for individuals with VWD and their families to understand the genetic basis of the condition and make informed decisions about family planning.

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

Future Trends

Media Gallary

References

https://emedicine.medscape.com/article/206996-overview